LeMaitre Vascular Management

Management criteria checks 3/4

LeMaitre Vascular's CEO is George LeMaitre, appointed in Jun 1992, has a tenure of 32.42 years. total yearly compensation is $2.22M, comprised of 26.7% salary and 73.3% bonuses, including company stock and options. directly owns 8.32% of the company’s shares, worth €190.26M. The average tenure of the management team and the board of directors is 14.6 years and 19 years respectively.

Key information

George LeMaitre

Chief executive officer

US$2.2m

Total compensation

CEO salary percentage	26.7%
CEO tenure	32.4yrs
CEO ownership	8.3%
Management average tenure	14.6yrs
Board average tenure	19yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has George LeMaitre's remuneration changed compared to LeMaitre Vascular's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	US$41m
Jun 30 2024	n/a	n/a	US$38m
Mar 31 2024	n/a	n/a	US$34m
Dec 31 2023	US$2m	US$593k	US$30m
Sep 30 2023	n/a	n/a	US$27m
Jun 30 2023	n/a	n/a	US$25m
Mar 31 2023	n/a	n/a	US$21m
Dec 31 2022	US$2m	US$568k	US$21m
Sep 30 2022	n/a	n/a	US$21m
Jun 30 2022	n/a	n/a	US$22m
Mar 31 2022	n/a	n/a	US$27m
Dec 31 2021	US$2m	US$473k	US$27m
Sep 30 2021	n/a	n/a	US$28m
Jun 30 2021	n/a	n/a	US$29m
Mar 31 2021	n/a	n/a	US$24m
Dec 31 2020	US$1m	US$311k	US$21m
Sep 30 2020	n/a	n/a	US$19m
Jun 30 2020	n/a	n/a	US$16m
Mar 31 2020	n/a	n/a	US$18m
Dec 31 2019	US$1m	US$438k	US$18m
Sep 30 2019	n/a	n/a	US$19m
Jun 30 2019	n/a	n/a	US$18m
Mar 31 2019	n/a	n/a	US$23m
Dec 31 2018	US$1m	US$438k	US$23m
Sep 30 2018	n/a	n/a	US$21m
Jun 30 2018	n/a	n/a	US$22m
Mar 31 2018	n/a	n/a	US$18m
Dec 31 2017	US$889k	US$162k	US$17m

Compensation vs Market: George's total compensation ($USD2.22M) is above average for companies of similar size in the German market ($USD1.64M).

Compensation vs Earnings: George's compensation has been consistent with company performance over the past year.

CEO

George LeMaitre (59 yo)

32.4yrs

Tenure

US$2,220,797

Compensation

Mr. George W. LeMaitre has been Chief Executive Officer of Lemaitre Vascular, Inc. since June 1992 and has been its Chairman since 2004. Mr. LeMaitre served as the President of Lemaitre Vascular from June...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
George LeMaitre	Chairman & CEO	32.4yrs	US$2.22m	8.32% € 190.3m
David Roberts	President & Director	17.3yrs	US$1.13m	0.063% € 1.4m
Joseph Pellegrino	CFO, Secretary & Director	17.3yrs	US$1.07m	0.039% € 895.6k
Trent Kamke	Senior Vice President of Operations	19.8yrs	US$670.38k	0.0071% € 161.6k
George LeMaitre	Founder and Chairman of Scientific Advisory Board	41.8yrs	US$138.40k	no data
Kimberly Cieslak	Vice President of Marketing	21.8yrs	no data	no data
Daniel Mumford	Senior Director of Human Resources	4.8yrs	no data	no data
Jonathan Ngau	Senior Vice President of Information Technology	less than a year	no data	no data
Maik Helmers	Senior Vice President of Sales – Central Europe	less than a year	no data	no data
Ryan Connelly	Senior Vice President of Advanced Manufacturing Engineering	1.8yrs	no data	no data
Andrew Hodgkinson	Senior Vice President of Clinical	11.8yrs	no data	no data
Stephane Maier	Senior Vice President of EMEA Operations	4.1yrs	no data	no data

14.6yrs

Average Tenure

50.5yo

Average Age

Experienced Management: LHU's management team is seasoned and experienced (14.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
George LeMaitre	Chairman & CEO	32.4yrs	US$2.22m	8.32% € 190.3m
David Roberts	President & Director	23.5yrs	US$1.13m	0.063% € 1.4m
Joseph Pellegrino	CFO, Secretary & Director	8.1yrs	US$1.07m	0.039% € 895.6k
George LeMaitre	Founder and Chairman of Scientific Advisory Board	no data	US$138.40k	no data
Lawrence Jasinski	Independent Director	21.8yrs	US$153.50k	0.019% € 427.9k
Thomas Naslund	Member of Scientific Advisory Board	no data	no data	no data
Steven Kagan	Member of Scientific Advisory Board	no data	no data	no data
Herbert Dardik	Member of Scientific Advisory Board	no data	no data	no data
Alan Dardik	Member of Scientific Advisory Board	no data	no data	no data
William Jordan	Member of Scientific Advisory Board	no data	no data	no data
John O'Connor	Independent Director	16.2yrs	US$163.00k	0.21% € 4.9m
Bridget Ross	Independent Director	4.6yrs	US$144.50k	0.0052% € 119.8k

19.0yrs

Average Tenure

60yo

Average Age

Experienced Board: LHU's board of directors are seasoned and experienced ( 19 years average tenure).

LeMaitre Vascular Management

Management criteria checks 3/4

Key information

Recent management updates

President & Director recently sold €353k worth of stock

LeMaitre Vascular, Inc., Annual General Meeting, Jun 03, 2024

Chairman & CEO recently sold €6.4m worth of stock

Chairman & CEO recently sold €2.6m worth of stock

Chairman & CEO recently sold €411k worth of stock

President & Director recently sold €505k worth of stock

Recent updates

Third quarter dividend of US$0.16 announced

Lemaitre Vascular, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2024

Third quarter 2024 earnings released: EPS: US$0.50 (vs US$0.34 in 3Q 2023)

LeMaitre Vascular, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter dividend of US$0.16 announced

LeMaitre Vascular, Inc. Approves Quarterly Dividend, Payable on August 29, 2024

Second quarter 2024 earnings released: EPS: US$0.53 (vs US$0.36 in 2Q 2023)

LeMaitre Vascular, Inc. to Report Q2, 2024 Results on Aug 01, 2024

First quarter dividend of US$0.16 announced

President & Director recently sold €353k worth of stock

First quarter 2024 earnings released: EPS: US$0.44 (vs US$0.27 in 1Q 2023)

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

LeMaitre Vascular, Inc. to Report Q1, 2024 Results on May 02, 2024

LeMaitre Vascular, Inc., Annual General Meeting, Jun 03, 2024

Chairman & CEO recently sold €6.4m worth of stock

Upcoming dividend of US$0.16 per share

Fourth quarter dividend of US$0.16 announced

LeMaitre Vascular, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Full year 2023 earnings released: EPS: US$1.36 (vs US$0.94 in FY 2022)

LeMaitre Vascular, Inc. (NasdaqGM:LMAT) announces an Equity Buyback for $50 million worth of its shares.

LeMaitre Vascular, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Chairman & CEO recently sold €2.6m worth of stock

Upcoming dividend of US$0.14 per share at 1.1% yield

Third quarter 2023 earnings released: EPS: US$0.34 (vs US$0.25 in 3Q 2022)

LeMaitre Vascular, Inc. Approves Quarterly Dividend, Payable on November 30, 2023

Now 20% undervalued after recent price drop

LeMaitre Vascular, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Investor sentiment deteriorates as stock falls 19%

Upcoming dividend of US$0.14 per share at 1.0% yield

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2023, Fourth Quarter and Full Year Ending December 31, 2023

Second quarter 2023 earnings released: EPS: US$0.36 (vs US$0.16 in 2Q 2022)

LeMaitre Vascular, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Chairman & CEO recently sold €411k worth of stock

Upcoming dividend of US$0.14 per share at 0.8% yield

President & Director recently sold €505k worth of stock

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2023

First quarter 2023 earnings released: EPS: US$0.27 (vs US$0.28 in 1Q 2022)

Insufficient new directors

Senior Vice President of Operations recently sold €308k worth of stock

Full year 2022 earnings released: EPS: US$0.94 (vs US$1.27 in FY 2021)

LeMaitre Vascular, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Upcoming dividend of US$0.13 per share

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: EPS: US$0.25 (vs US$0.30 in 3Q 2021)

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

LeMaitre Vascular, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Lemaitre Vascular, Inc. Appoints Martha Shadan as Director

Upcoming dividend of US$0.13 per share

CFO, Treasurer recently sold €146k worth of stock

CFO, Treasurer recently sold €146k worth of stock

Second quarter 2022 earnings released: EPS: US$0.16 (vs US$0.40 in 2Q 2021)

LeMaitre Vascular, Inc. Approves Quarterly Dividend, Payable on September 8, 2022

LeMaitre Vascular, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Now 21% undervalued

First quarter 2022 earnings released: EPS: US$0.28 (vs US$0.29 in 1Q 2021)

LeMaitre Vascular, Inc. to Report Q1, 2022 Results on Apr 28, 2022

LeMaitre Vascular, Inc., Annual General Meeting, Jun 01, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

LeMaitre Vascular, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2022

LeMaitre Vascular, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

Upcoming dividend of US$0.11 per share

Third quarter 2021 earnings released: EPS US$0.30 (vs US$0.37 in 3Q 2020)

Upcoming dividend of US$0.11 per share

Second quarter 2021 earnings released: EPS US$0.40 (vs US$0.17 in 2Q 2020)

LeMaitre Vascular, Inc. has completed a Follow-on Equity Offering in the amount of $54.5 million.

LeMaitre Vascular, Inc.(NasdaqGM:LMAT) dropped from Russell 3000E Value Index

Upcoming dividend of US$0.11 per share